• 咨询热线
    客服服务热线 13671568941/15317326293
  • 在线咨询
  • 微信客服
    微信客服
  • 公众号
    扫码关注公众号

Quisinostat

CAS No. 875320-29-9

Quisinostat ( (JNJ-26481585) )

产品货号. M16360 CAS No. 875320-29-9

Quisinostat (JNJ-26481585) 是一种新型第二代 HDAC 抑制剂,对 HDAC1 具有最高效力,IC50 为 0.11 nM,对 HDAC 2、4、10 和 11 具有中等效力。

纯度: >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
规格 价格/人民币 库存 数量
5MG ¥900 有现货
10MG ¥1340 有现货
25MG ¥2186 有现货
50MG ¥3153 有现货
100MG ¥4608 有现货
200MG ¥6462 有现货
500MG 获取报价 有现货
1G 获取报价 有现货
1 mL x 10 mM in DMSO ¥979 有现货

生物学信息

  • 产品名称
    Quisinostat
  • 注意事项
    本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
  • 产品简述
    Quisinostat (JNJ-26481585) 是一种新型第二代 HDAC 抑制剂,对 HDAC1 具有最高效力,IC50 为 0.11 nM,对 HDAC 2、4、10 和 11 具有中等效力。
  • 产品描述
    Quisinostat (JNJ-26481585) is a novel second-generation HDAC inhibitor with highest potency for HDAC1 with IC50 of 0.11 nM, modest potent to HDACs 2, 4, 10, and 11; greater than 30-fold selectivity against HDACs 3, 5, 8, and 9 and lowest potency to HDACs 6 and 7. Phase 2.(In Vitro):Quisinostat inhibits HDAC isozymes in vitro.Quisinostat (30-1000 nM; 24 hours) is a potent pan-HDAC inhibitor in tumor cells.Quisinostat has a broad spectrum antiproliferative activity against solid and hematologic cancer cell lines and induces apoptosis.(In Vivo):Quisinostat (40 mg/kg; p.o.; once daily; for 3 days) acts as a potent HDAC1 inhibitor p21waf1,cip1 ZsGreen tumors in vivo.Quisinostat induces continuous H3 acetylation in tumor tissue in vivo.Quisinostat (10 mg/kg; once daily; i.p.; for 14 days) strongly inhibits the growth of large pre-established HCT116 colon xenografts.
  • 体外实验
    Quisinostat inhibits HDAC isozymes in vitro.Quisinostat (30-1000 nM; 24 hours) is a potent pan-HDAC inhibitor in tumor cells.?Quisinostat has a broad spectrum antiproliferative activity against solid and hematologic cancer cell lines and induces apoptosis. Western Blot Analysis Cell Line:Human A2780 ovarian carcinoma cellsConcentration:30 nM, 100 nM, 300 nM, 1000 nM Incubation Time:24 hours Result:Induced H3 and H4 acetylation at concentrations as low as 30 to 100 nM.
  • 体内实验
    Quisinostat (40 mg/kg; p.o.; once daily; for 3 days) acts as a potent HDAC1 inhibitor that inhibits p21waf1,cip1 ZsGreen tumors in vivo.Quisinostat induces continuous H3 acetylation in tumor tissue in vivo.Quisinostat (10 mg/kg; once daily; i.p.; for 14 days) strongly inhibits the growth of large pre-established HCT116 colon xenografts. Animal Model:NMRI nude mice, with HCT116 colon carcinoma cells xenografts Dosage:10 mg/kg Administration: Intraperitoneal injection, once daily, for 14 days Result:Strongly inhibited the growth of large pre-established HCT116 colon xenografts.
  • 同义词
    (JNJ-26481585)
  • 通路
    Cell Cycle/DNA Damage
  • 靶点
    HDAC
  • 受体
    HDAC1| HDAC10| HDAC11| HDAC2| HDAC3| HDAC4| HDAC5| HDAC8
  • 研究领域
    Cancer
  • 适应症
    ——

化学信息

  • CAS Number
    875320-29-9
  • 分子量
    394.476
  • 分子式
    C21H26N6O2
  • 纯度
    >98% (HPLC)
  • 溶解度
    DMSO:79 mg/mL (200.26 mM); Ethanol:<1 mg/mL (<1 mM); Water:<1 mg/mL (<1 mM)
  • SMILES
    O=C(C1=CN=C(N2CCC(CNCC3=CN(C)C4=C3C=CC=C4)CC2)N=C1)NO
  • 化学全称
    N-hydroxy-2-(4-((((1-methyl-1H-indol-3-yl)methyl)amino)methyl)piperidin-1-yl)pyrimidine-5-carboxamide

运输与储存

  • 储存条件
    (-20℃)
  • 运输条件
    With Ice Pack
  • 稳定性
    ≥ 2 years

参考文献

1.Arts J, et al. Clin Cancer Res, 2009, 15(22), 6841-685
产品手册
关联产品
  • Encorafenib

    LGX818是一种口服的突变BRaf V600E抑制剂(IC50=0.3 nM),具有潜在的抗肿瘤活性。

  • BRD4097

    BRD4097, a negative control in the HDAC1/2/3/8 assay, is a selective histone deacetylase (HDAC3) inhibitor that can be used to protect b-cells and improve insulin resistance, help promote cognitive function and enhance learning and memory formation.

  • Pandacostat

    Pandacostat 是第一个非选择性 HDAC 抑制剂 (pan-HDACi)。